Neurotoxicity of Clostridium perfringens Epsilon-Toxin for the Rat Hippocampus via the Glutamatergic System

The neurotoxicity of epsilon-toxin, one of the major lethal toxins produced by Clostridium perfringens type B, was studied by histological examination of the rat brain. When the toxin was injected intravenously at a lethal dose (100 ng/kg), neuronal damage was observed in many areas of the brain. Injection of the toxin at a sublethal dose (50 ng/kg) caused neuronal damage predominantly in the hippocampus: pyramidal cells in the hippocampus showed marked shrinkage and karyopyknosis, or so-called dark cells. The dark cells lost the immunoreactivity to microtubule-associated protein-2, a postsynaptic somal and dendric marker, while acetylcholinesterase-positive fibers were not affected. Timm’s zinc staining revealed that zinc ions were depleted in the mossy layers of the CA3 subfield containing glutamate as a synaptic transmitter. The cerebral blood flow in the hippocampus was not altered significantly before or after administration of the toxin, as measured by laser-Doppler flowmetry, excluding the possibility that the observed histological change was due to a secondary effect of ischemia in the hippocampus. Prior injection of either a glutamate release inhibitor or a glutamate receptor antagonist protected the hippocampus from the neuronal damage caused by epsilon-toxin. These results suggest that epsilon-toxin acts on the glutamatergic system and evokes excessive release of glutamate, leading to neuronal damage.     

Diagnosis of visceral leishmaniasis: comparative potential of amastigote antigen,recombinant antigen and PCR

Development of simple, economical and non-invasive tests for the early diagnosis of visceral leishmaniasis (VL) or kala-azar (KA) remains a challenge, and serological studies based on antigen prepared from the amastigote stage of Leishmania donovani, the stage that causes infection, are lacking. In the present study, circulating antibodies to total antigen isolated from the promastigote and amastigote stages of the parasite, as well as to recombinant K39 (rK39) antigen, are measured by enzyme-linked immunosorbent assay (ELISA) and the results compared with a polymerase chain reaction (PCR) test for KA diagnosis. In 116 samples of KA examined, the amastigote antigen gave significantly higher mean absorbance values in ELISA than did the promastigote antigen. The sensitivity for KA detection was significantly higher using the amastigote antigen (94%) than the promastigote antigen (90.5%). Analysis in 91 controls showed that specificity was higher with amastigote antigen (92.3%) than with promastigote antigen (86.8-89.0%). Reliability of ELISA diagnosis with amastigote antigen was only marginally lower than that with rK39 ELISA or with the PCR test. Easy availability and low cost of indigenous amastigote antigen, together with the simplicity of ELISA compared with PCR, make ELISA based on amastigote antigen a promising choice for the diagnosis of KA.     

Depression of long term potentiation in gerbil hippocampus following postischemic hypothermia

To investigate the mechanism of chronic cell death following postischemic hypothermia, the change of N-methyl- -aspartate receptor (NMDAR) were examined by immunohistochemistry of NMDAR1 and long-term potentiation (LTP) in the CA1 subfield of the gerbil hippocampus. At 1 week following postischemic hypothermia (32°C×4 h), all CA1 neurons survived; however, immunoreactivity of NMDAR1 increased in neuronal perikarya whereas decreased in dendrites in the CA1 neurons. The abnormality was still observed in remaining CA1 neurons at 1 month after hypothermia. LTP was also significantly depressed at 1 week after hypothermia. These results suggest that some abnormalities in the glutamate receptor may be caused by ischemia; such abnormality would persist in spite of hypothermia treatment, resulting in the depression of LTP.     

Biomarker associations with insomnia and secondary sleep outcomes in persons with and without HIV in the POPPY-Sleep substudy: a cohort study

Study ObjectivesWe investigated associations between inflammatory profiles/clusters and sleep measures in people living with HIV and demographically-/lifestyle-similar HIV-negative controls in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY)-Sleep substudy.MethodsPrimary outcome was insomnia (Insomnia Severity Index [ISI]>15). Secondary sleep outcomes included 7-day actigraphy (e.g. mean/standard deviation of sleep duration/efficiency), overnight oximetry (e.g. oxygen desaturation index [ODI]) and patient-reported measures (Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires). Participants were grouped using Principal Component Analysis of 31 biomarkers across several inflammatory pathways followed by cluster analysis. Between-cluster differences in baseline characteristics and sleep outcomes were assessed using Kruskal–Wallis/logistic regression/Chi-squared/Fisher’s exact tests.ResultsOf the 465 participants included (74% people with HIV, median [interquartile range] age 54 [50–60] years), only 18% had insomnia and secondary sleep outcomes suggested generally good sleep (e.g. ODI 3.1/hr [1.5–6.4]). Three clusters with distinct inflammatory profiles were identified: “gut/immune activation” (n = 47), “neurovascular” (n = 209), and “reference” (relatively lower inflammation; n = 209). The “neurovascular” cluster included higher proportions of people with HIV, obesity (BMI>30 kg/m²), and previous cardiovascular disease, mental health disorder, and arthritis of knee/hip relative to the other two clusters. No clinically relevant between-cluster differences were observed in proportions with insomnia (17%, 18%, 20%) before (p = .76) or after (p = .75) adjustment for potential confounders. Few associations were observed among actigraphy, oximetry, and PROMIS measures.ConclusionsAlthough associations could exist with other sleep measures or biomarker types not assessed, our findings do not support a strong association between sleep and inflammation in people with HIV.     

Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro,ex vivo and in vivo investigations

Abstract

A receptor level interaction of etoposide with P-glycoprotein (P-gp) and subsequent intestinal efflux has an adverse effect on its oral absorption. The present work is aimed to enhance the bioavailability of etoposide by co-administering it with quercetin (a P-gp inhibitor) in dual-loaded polymeric nanoparticle formulation. Poly-lactic-co-glycolic acid (PLGA) nanoparticles were optimized for various parameters like o/w phase volume ratio, poly-vinyl alcohol concentration, PLGA concentration and sonication time. The cytotoxicity studies (MTT assay) revealed a 9- and 11-fold decrease in the IC 50 values for etoposide-loaded nanoparticles (ENP) and etoposide?+?quercetin dual-loaded nanoparticles (EQNP) when compared to that of free etoposide, respectively, and the results were further supported by florescent-activated cell sorter studies. The confocal imaging of the intestinal sections treated with ENP and EQNP containing fluorescent probe (rhodamine) showed the superiority of the EQNP to permeate deeper. Furthermore, pharmacokinetic studies on rats revealed that EQNP exhibited a 2.4-fold increase in bioavailability of etoposide than ENP with no quercetin. The developed loaded nanoparticles have the high potential to enhance the bioavailability of the etoposide and sensitize the resistant cells.     

A synthetic porphyrin as an effective dual antidote against carbon monoxide and cyanide poisoning

Simultaneous poisoning by carbon monoxide (CO) and hydrogen cyanide is the major cause of mortality in fire gas accidents. Here, we report on the invention of an injectable antidote against CO and cyanide (CN^–) mixed poisoning. The solution contains four compounds: iron(III)porphyrin (Fe^IIITPPS, F), two methyl-β-cyclodextrin (CD) dimers linked by pyridine (Py3CD, P) and imidazole (Im3CD, I), and a reducing agent (Na₂S₂O₄, S). When these compounds are dissolved in saline, the solution contains two synthetic heme models including a complex of F with P (hemoCD-P) and another one of F with I (hemoCD-I), both in their iron(II) state. hemoCD-P is stable in its iron(II) state and captures CO more strongly than native hemoproteins, while hemoCD-I is readily autoxidized to its iron(III) state to scavenge CN^– once injected into blood circulation. The mixed solution (hemoCD-Twins) exhibited remarkable protective effects against acute CO and CN^– mixed poisoning in mice (~85% survival vs. 0% controls). In a model using rats, exposure to CO and CN^– resulted in a significant decrease in heart rate and blood pressure, which were restored by hemoCD-Twins in association with decreased CO and CN^– levels in blood. Pharmacokinetic data revealed a fast urinary excretion of hemoCD-Twins with an elimination half-life of 47 min. Finally, to simulate a fire accident and translate our findings to a real-life scenario, we confirmed that combustion gas from acrylic cloth caused severe toxicity to mice and that injection of hemoCD-Twins significantly improved the survival rate, leading to a rapid recovery from the physical incapacitation.

Fire accidents frequently occur around the world and the consequent inhalation of combustion gases represents the leading cause of death under these circumstances (1–10). Typically, combustion gases consist, among others, of carbon dioxide, water (H₂O), carbon monoxide (CO), hydrogen cyanide (HCN), hydrochloric acid, nitrogen oxide, and sulfur oxide. Their amounts depend on the materials of combustion (3–10) and, among them, CO and HCN are the most dangerous due to their severe toxic effects in humans (3–4, 5–15). CO is generated during incomplete combustion of carbon materials while HCN derives from carbon- and nitrogen-containing materials. Thus, CO and HCN gases are simultaneously released when synthetic materials such as plastics, acrylic cloths, and urethanes are burned in buildings. Once inhaled, CO strongly binds to ferrous iron(II) heme proteins such as hemoglobin (Hb) in erythrocytes and myoglobin in muscles (16–19), thus compromising oxygen (O₂) transport/storage in the blood circulation and tissues. On the contrary, HCN binds as cyanide ion (CN^–) to ferric iron(III) heme, preferentially targeting cytochrome c oxidase (CcO) in mitochondria and interrupting O₂-dependent energy production (11, 20–22). Likewise, the toxic effects of CO on mitochondrial respiration are ascribed to its ability to bind to cytochrome c oxidase (23–25). Therefore, both CO and HCN can inhibit aerobic respiration mediated by several heme proteins leading to anoxia-induced lethal toxicity. As the molecular mechanisms of CO and HCN toxicity are closely related, additional or synergistic deleterious effects can be expected when these two gases are produced and inhaled at the same time (26–31). Therapeutic strategies to treat either CO or HCN poisoning have been developed independently (11, 13, 22, 32–37). However, to our knowledge, there is no medical intervention at present to neutralize simultaneously CO and HCN with an effective treatment in vivo.In the present study, we have developed an injectable antidote for CO and HCN mixed poisoning. This agent contains supramolecular compounds, termed hemoCDs, composed of a water-soluble iron(II/III)porphyrin and two cyclodextrin (CD) dimers. Based on our previous research on the synthesis and characterization of heme protein model structures (38–40), the gas-binding ability and the redox status of the iron center of the porphyrin can be regulated by the linker structure of the CD dimers englobing the porphyrin. The porphyrin complexed with a CD dimer having a pyridine linker (hemoCD-P, Fig. 1 A, Left) is stable in the iron(II) state in vivo and shows much higher CO-binding affinity compared to the affinities reported for native heme proteins (41–45). On the contrary, the porphyrin complexed with a CD dimer having an imidazole linker (hemoCD-I, Fig. 1 A, Right) is stable in the iron(III) state and shows a higher binding affinity to CN^– than native ferric met-hemoglobin (met-Hb) (46, 47). These two complexes do not bind to plasma proteins in the circulation when injected separately and are quickly excreted in urines without any chemical decomposition. Therefore, these compounds have the ability to capture either CO or CN^– to their iron(II/III) centers in vivo and expel these toxic ligands from the organism (41–47). Here, we have developed hemoCD-Twins that contains both hemoCD-P and hemoCD-I in saline for simultaneous removal of CO and HCN in vivo. This paper describes the primary pharmacological properties of hemoCD-Twins and its detoxification effects in animals intoxicated with CO and CN^–. To simulate a real-life fire accident, the burning of acrylic cloth with consequent release of combustion gases was also used as an experimental approach for antidotal tests. We found that hemoCD-Twins exhibits the following features: 1) The synthetic compounds are storable at room temperature over a year thanks to their chemical stability; 2) the solution can be quickly prepared without the need of special handlings; 3) a single administration of hemoCD-Twins shows immediate dual antidotal effect against CO and CN^–; and 4) the injected solution is quickly eliminated from the body without significant side effects. We are envisioning a scenario whereby a person who is accidentally exposed to fire gases containing CO and HCN can be promptly treated at the site by infusion with hemoCD-Twins.Open in a separate windowFig. 1.hemoCD-Twins as an antidote system against CO and CN^– mixed poisoning. (A) Biomimetic heme protein model compounds hemoCD-P and hemoCD-I that are used as CO and CN^– scavengers in vivo. (B) Chemical structures of the four components P, I, F, and S contained in hemoCD-Twins. (C) Preparation of hemoCD-Twins. Three powder compounds, F, P, and I, were dissolved in PBS in a 2:1:1 molar ratio, where the solution contains hemoCD-P and hemoCD-I in ferric iron(III) states. The solution is stable and storable at room temperature. The reducing agent S is added just before use. (D) Schematic illustration for the simultaneous removal of CO and CN^– by a single injection of hemoCD-Twins in vivo. CO and CN^– are removed from living organisms and excreted in the urine with hemoCD-P and hemoCD-I in ferrous iron(II) and ferric iron(III) complexes, respectively.